/CLGN
CLGN Stock - CollPlant Biotechnologies Ltd.
Healthcare|BiotechnologyNASDAQ
$1.52+10.14%
+$0.14 (+10.14%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.93
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+722.4%upside
Target: $12.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CLGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.50 – $1.54
TARGET (TP)$12.50
STOP LOSS$1.40
RISK/REWARD1:91.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.67
52W High$4.98
52W Low$1.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $515,000 | $10.96M | $299,000 | $15.64M | $6.14M |
| Gross Profit | $-2,148,000 | $7.87M | $-1,177,000 | $13.64M | $2.68M |
| Gross Margin | -417.1% | 71.8% | -393.6% | 87.2% | 43.7% |
| Operating Income | $-17,251,000 | $-7,512,000 | $-17,097,000 | $65,000 | $-5,599,000 |
| Net Income | $-16,609,000 | $-7,019,000 | $-16,925,000 | $237,000 | $-5,774,000 |
| Net Margin | -3225.0% | -64.0% | -5660.5% | 1.5% | -94.1% |
| EPS | $-1.45 | $-0.62 | $-1.52 | $0.04 | $-0.84 |
Company Overview
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$23
Average Target
↑ 1396.7% Upside
Now
$23
Low
$23
Average
$23
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 17th 2023 | Alliance Global Partners | Initiation | Buy | $22.75 |
Earnings History & Surprises
CLGNBeat Rate
21%
Last 19 quarters
Avg Surprise
+83.3%
EPS vs Estimate
Beats / Misses
4/15
Last 12 quarters
Latest EPS
$-0.27
Q4 2025
EPS Surprise History
Q1 24
-242.9%
$-0.24vs$-0.07
Q2 24
-20.0%
$-0.42vs$-0.35
Q3 24
-5.7%
$-0.37vs$-0.35
Q4 24
-35.7%
$-0.38vs$-0.28
Q1 25
+19.0%
$-0.34vs$-0.42
Q2 25
+64.9%
$-0.13vs$-0.37
Q3 25
-180.0%
$-0.28vs$-0.10
Q4 25
-171.1%
$-0.27vs$0.38
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 26, 2025 | $0.38 | $-0.27 | -171.1% | ✗ MISS |
Q3 2025 | Aug 20, 2025 | $-0.10 | $-0.28 | -180.0% | ✗ MISS |
Q2 2025 | May 28, 2025 | $-0.37 | $-0.13 | +64.9% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-0.42 | $-0.34 | +19.0% | ✓ BEAT |
Q4 2024 | Nov 27, 2024 | $-0.28 | $-0.38 | -35.7% | ✗ MISS |
Q3 2024 | Aug 20, 2024 | $-0.35 | $-0.37 | -5.7% | ✗ MISS |
Q2 2024 | Apr 4, 2024 | $-0.35 | $-0.42 | -20.0% | ✗ MISS |
Q1 2024 | Jan 25, 2024 | $-0.07 | $-0.24 | -242.9% | ✗ MISS |
Q4 2023 | Nov 29, 2023 | $-0.13 | $-0.38 | -192.3% | ✗ MISS |
Q3 2023 | Aug 24, 2023 | $0.01 | $0.49 | +3166.7% | ✓ BEAT |
Q2 2023 | May 24, 2023 | $-0.29 | $-0.33 | -13.8% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-0.21 | $-0.39 | -85.7% | ✗ MISS |
Q4 2022 | Dec 1, 2022 | $-0.31 | $-0.40 | -29.0% | ✗ MISS |
Q3 2022 | Aug 25, 2022 | $-0.08 | $-0.39 | -387.5% | ✗ MISS |
Q2 2022 | May 26, 2022 | $-0.14 | $-0.36 | -157.1% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.26 | $-0.30 | -15.4% | ✗ MISS |
Q4 2021 | Nov 18, 2021 | $-0.28 | $-0.29 | -3.6% | ✗ MISS |
Q3 2021 | Aug 19, 2021 | $-0.10 | $-0.30 | -200.0% | ✗ MISS |
Q2 2021 | May 27, 2021 | $0.51 | $0.88 | +72.5% | ✓ BEAT |
Latest News
D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $12 Price Target
📈 PositiveBenzinga•Nov 28, 2025, 02:06 PM
CollPlant Biotechnologies shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 26, 2025, 02:00 PM
CollPlant Biotechnologies Q3 Adj. EPS $(0.25) Misses $0.15 Estimate, Sales $77.000K Miss $4.845M Estimate
📉 NegativeBenzinga•Nov 26, 2025, 12:43 PM
D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $12 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 01:27 PM
CollPlant Reports Technion Study Results Showing Collink.3D Provides Consistent, Tunable, And Animal-Free Alternative To Matrigel
📈 PositiveBenzinga•Oct 20, 2025, 11:07 AM
Mayo Clinic Develops First Fully Humanized 3D Bioprinted Skin Model Using CollPlant's Plant-Derived rhCollagen
📈 PositiveBenzinga•Oct 16, 2025, 11:07 AM
CollPlant Biotechnologies Announced That Researchers From Mayo Clinic Have Developed The First Fully Humanized 3D Bioprinted Skin Model Using CollPlant's Plant-derived rhCollagen
📈 PositiveBenzinga•Oct 16, 2025, 11:06 AM
CollPlant Biotechnologies Announces Results From Non-Clinical Program Evaluating Photocurable Dermal Filler; Plans To Advance Product Candidate Into Clinical Trials
📈 PositiveBenzinga•Sep 30, 2025, 11:04 AM
D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $12 Price Target
📈 PositiveBenzinga•Sep 16, 2025, 11:07 AM
HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target
📈 PositiveBenzinga•Aug 21, 2025, 11:27 AM
CollPlant Biotechnologies shares are trading lower after the company reported worse-than-expected Q2 financial results.
📉 NegativeBenzinga•Aug 20, 2025, 03:49 PM
CollPlant Biotechnologies Q2 Adj. EPS $(0.23) Misses $(0.14) Estimate, Sales $179.000K Miss $2.544M Estimate
📉 NegativeBenzinga•Aug 20, 2025, 11:01 AM
CollPlant shares rises on expanded partnership with STEMCELL Technologies
📈 PositiveSeeking Alpha•Jun 9, 2025, 11:40 AM
CollPlant Biotechnologies shares slide after announces capital raise $3.6M through registered direct offering
📉 NegativeSeeking Alpha•May 30, 2025, 11:34 AM
Frequently Asked Questions about CLGN
What is CLGN's current stock price?
CollPlant Biotechnologies Ltd. (CLGN) is currently trading at $1.52 per share. The stock has moved +10.14% today.
What is the analyst price target for CLGN?
The average analyst price target for CLGN is $12.50, based on 1 analyst.
What sector is CollPlant Biotechnologies Ltd. in?
CollPlant Biotechnologies Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CLGN's market cap?
CollPlant Biotechnologies Ltd. has a market capitalization of $0.02 billion, making it a small-cap company.
Does CLGN pay dividends?
No, CollPlant Biotechnologies Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCVKD
Cadrenal Therapeutics, Inc. Common Stock
$7.11
Mkt Cap: $0.0B
ENLV
Enlivex Therapeutics Ltd.
$0.83
Mkt Cap: $0.0B
KLTO
Klotho Neurosciences, Inc.
$0.39
Mkt Cap: $0.0B
MTVA
MetaVia Inc.
$8.62
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
NRXS
NeurAxis, Inc.
$3.22
Mkt Cap: $0.0B
RLYB
Rallybio Corporation
$0.79
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to CLGN for comparison